top of page

Biolexis Therapeutics launches Metabolexis to develop novel oral medicines for obesity and T2DM

Biolexis Therapeutics, a clinical-stage AI-enabled drug discovery company, has launched Metabolexis, a new pipeline company developing three targeted oral small molecules for the treatment of Obesity and Type 2 Diabetes.

"We believe that our novel small molecule therapeutics delivered orally can address some of the toxicity and delivery complications associated with today's treatments," said Dr David Bearss, CEO and co-founder of Biolexis Therapeutics. "With the launch of Metabolexis, we have an opportunity to address this immense need by providing clinically effective, easily administered, and economically viable treatments that improve the lives of these patients."

The Metabolexis pipeline includes isoform-specific activators of AMPK, aGLP-1/GLP-1R agonists, and mTORC1 inhibitors with plans to file Investigational New Drug Applications (INDs) for all three agents by the end of Q4 2024 and to initiate First-In-Human Phase I safety clinical trials in Q1 2025. Utilising Biolexis' MolecuLern process, the company has identified lead candidates currently in pre-clinical development.

MolecuLern is an AI-enabled drug discovery process that leverages empirical/wet lab data-driven models trained on Biolexis' curated and proprietary library, including physical and virtual synthesis-ready fragments and NCEs, to identify lead molecules targeting any class of protein. This innovative and expedited process results in candidates with drug-like characteristics, reducing development costs, increasing the potential for clinical trial effectiveness, and significantly accelerating the drug discovery time frame.

"Obesity-related conditions, including type-2 diabetes, cardiometabolic, stroke and age-related diseases, continue to be crucial issues in our communities," said Dr Hariprasad Vankayalapati, CSO and co-founder of Biolexis Therapeutics. "As we continue to research, develop, and implement innovative methods to address critical unmet medical needs, we believe our work in activating AMPK, agonising GLP-1, and inhibiting mTORC1 targets will expand treatment options for patients with these and other metabolic disorders."

Metabolexis will focus on targeting these important conditions with the goal to eliminate the presence of the major chronic conditions associated with aging. The work at Metabolexis will focus on targeting known regulators and pathways that control the aging process and will develop drugs intended to improve the health of the aging population.


bottom of page